AstraZeneca Enlists Owlstone Medical To Identify Asthma And COPD Biomarkers
Owlstone Medical has signed another major collaboration agreement with a big pharma company to use its breath biopsy services. The Cambridge, UK company is partnering with AstraZeneca to to identify novel breath biomarkers for asthma and COPD.
You may also be interested in...
The inhalation devices market will reach $12bn by 2023, driven by the rising prevalence of asthma and COPD worldwide. GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim dominate worldwide sales of inhalation products for asthma and COPD, and are facing generic competition. Generics developers and major pharma players are trying to set themselves apart with better drug-delivery devices.
CMR Surgical CEO Martin Frost is making way for a new boss to lead the surgical robotics company. Per Vegard Nerseth is set to join CMR Surgical in January 2020 as the company gears up for its most ambitious year yet.
Device Week, 29 November 2019 – Top Clinical Trial News From AHA & Investment Forecast From Jefferies 2019
In this week's Medtech Insight podcast, deputy editor Reed Miller discusses clinical trial news from the annual American Heart Association (AHA) meeting, and senior reporter Catherine Longworth highlights goings-on at the Jefferies Healthcare Conference in London.